Latest Articles
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative
Published: Nov. 13, 2025, 9:25 p.m.
Insufficient Endometrial Biopsy Increases Cancer Risk - European Medical Journal
Insufficient Endometrial Biopsy Increases Cancer Risk European Medical Journal
Published: Nov. 13, 2025, 1:03 p.m.
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech
Published: Nov. 13, 2025, 9 a.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare
Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork
Published: Nov. 12, 2025, 7:12 p.m.
Sylvester Comprehensive Cancer Center Launches Clinical Trial on Fasting for Endometrial Cancer - University of Miami
Sylvester Comprehensive Cancer Center Launches Clinical Trial on Fasting for Endometrial Cancer University of Miami
Published: Nov. 12, 2025, 1:59 p.m.
Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative - Nature
Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative Nature
Published: Nov. 11, 2025, 8:42 p.m.
'It took a year to get diagnosed with cancer because the doctor missed one symptom' - Daily Express US
'It took a year to get diagnosed with cancer because the doctor missed one symptom' Daily Express US
Published: Nov. 11, 2025, 4:56 p.m.
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models - Frontiers
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models Frontiers
Published: Nov. 11, 2025, 4:15 p.m.
Adverse Event and Quality-of-Life Considerations in Endometrial Cancer - OncLive
Adverse Event and Quality-of-Life Considerations in Endometrial Cancer OncLive
Published: Nov. 10, 2025, 1:37 p.m.
Link copied to clipboard!